Colitis, UlcerativePhase 3DUET ENCORE-UCNCT07577856
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study testing JNJ-78934804 and Guselkumab in people with Colitis, Ulcerative, run by Janssen Research & Development, LLC at 318 sites in 33 countries.
Trial summary
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colitis, Ulcerative
- What is being tested?
- JNJ-78934804 and Guselkumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 644 participants
- Where
- 318 sitesin 33 countries
- Study dates
- 23 May 2026to 16 Oct 2030
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC.
- Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy
- An endoscopy subscore >=2 as obtained during central review of the screening video endoscopy
- Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies
Who cannot join
- Isolated proctitis (UC limited to the rectum only or to less than [<] 20 centimeter [cm] from the anal verge) as determined during central review of the screening video endoscopy OR Has a diagnosis of isolated proctitis
- Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or any findings suggestive of CD
- Has a history of or ongoing chronic or recurrent infectious disease
- Has previously demonstrated inadequate initial response, loss of response, allergy, hypersensitivity or intolerance to guselkumab or to golimumab
- Is a participant who is pregnant, breastfeeding, or planning to become pregnant, or plans to father a child, while enrolled in this study or within 6 months after the last dose of study intervention
Trial locations and contacts
318 sites in 33 countries. Contact the study team or a site near you to ask about taking part.
318 sites in 33 countries
United States30 sites, 30 recruiting
- Recruiting
Clinnova Research
Anaheim, California, 92805
- Recruiting
University of North Carolina Hospital
Chapel Hill, North Carolina, 27599-7080
- Recruiting
Gastro SB Clinic
Chula Vista, California, 91910
- Recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907
- Recruiting
Gastro One
Cordova, Tennessee, 38018
- Recruiting
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky, 41017
- Recruiting
Michigan Center of Medical Research
Farmington Hill, Pennsylvania, 48334
- Recruiting
Gastroenterology Clinic of Acadiana
Lafayette, Louisiana, 70503
- Recruiting
Florida Research Center Inc.
Lakewood Rch, Florida, 34211
- Recruiting
GIA Kansas City
Lee's Summit, Missouri, 64086
- Recruiting
United Medical Doctors
Los Alamitos, California, 90720
- Recruiting
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, 44060
- Recruiting
GIA Metairie
Metairie, Louisiana, 70006
- Recruiting
Sanchez Clinical Research, Inc
Miami, Florida, 33157-6575
- Recruiting
New York Gastroenterology Associates
New York, New York, 10075
- Recruiting
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma, 73114
- Recruiting
Endoscopic Research Inc
Orlando, Florida, 32803-1853
- Recruiting
The Oregon Clinic
Portland, Oregon, 97220
- Recruiting
GIA Richmond
Richmond, Virginia, 23229
- Recruiting
Southern Star Research Institute, LLC
San Antonio, Texas, 78229
- Recruiting
Medical Associates Research Group, Inc.
San Diego, California, 92123
- Recruiting
Mayo Clinic
Scottsdale, Arizona, 85259
- Recruiting
Palmetto Primary and Specialty Care Physicians, Charleston
Summerville, South Carolina, 29486
- Recruiting
GIA Sun City
Sun City, Arizona, 85351
- Recruiting
Atlanta Gastroenterology Specialists
Suwanee, Georgia, 30024
- Recruiting
GI Alliance Tacoma
Tacoma, Washington, 98405
- Recruiting
GCP Clinical Research
Tampa, Florida, 33609
- Recruiting
Tyler Research Institute, LLC
Tyler, Texas, 75701
- Recruiting
Frontier Clinical Research
Uniontown, Pennsylvania, 15401
- Recruiting
GIA Webster
Webster, Texas, 77598
China27 sites, 27 recruiting
- Recruiting
China Japan Friendship Hospital
Beijing, 100013
- Recruiting
Beijing Friendship Hospital Capital Medical University
Beijing, 100050
- Recruiting
Peking University Third Hospital
Beijing, 100191
- Recruiting
Peking Union Medical College Hospital
Beijing, 100730
- Recruiting
Changzhou No 2 Peoples Hospital
Changzhou, 213000
- Recruiting
West China Hospital Si Chuan University
Chengdu, 610041
- Recruiting
Chongqing General Hospital
Chongqing, 400014
- Recruiting
The First People's Hospital of Foshan
Foshan, 528010
- Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, 350004
- Recruiting
The First Affiliated Hospital Sun Yat sen University
Guangzhou, 510080
- Recruiting
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510260
- Recruiting
Sun Yat-sen University - The Sixth Affiliated Hospital Guangdong Gastrointestinal Hospital
Guangzhou, 510655
- Recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, 310016
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, 230022
- Recruiting
Huai'an 1st Hospital
Huai'an, 223300
- Recruiting
Jinhua municipal central hospital
Jinhua, 321013
- Recruiting
Lanzhou University Second Hospital
Lanzhou, 730030
- Recruiting
The first affiliated hospital of Henan University of science and technology
Luoyang, 471003
- Recruiting
Ningbo medical center lihuili hospital
Ningbo, 315000
- Recruiting
Ruijin Hospital Shanghai Jiao Tong University
Shanghai, 200025
- Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, 050000
- Recruiting
Taihe Hospital
Shiyan, 442000
- Recruiting
Second Affiliated Hospital, SooChow University
Suzhou, 215004
- Recruiting
Zhongshan Hospital, Xiamen University
Xiamen, 361004
- Recruiting
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, 450014
- Recruiting
ZhuZhou Central Hospital
Zhuzhou, 412007
- Recruiting
Affiliated Hospital of Zunyi Medical University
Zunyi, 563099
Japan25 sites, 25 recruiting
- Recruiting
Institute of Science Tokyo Hospital
Bunkyō City, 113 8519
- Recruiting
Hamamatsu University Hospital
Hamamatsu, 431-3192
- Recruiting
Matsuda Hospital
Hamamatsu, 432-8061
- Recruiting
National Hospital Organization Mito Medical Center
Higashiharima, 311-3193
- Recruiting
Kagoshima IBD Gastroenterology Clinic
Kagoshima, 892-0843
- Recruiting
Tsujinaka Hospital Kashiwanoha
Kashiwa, 277-0871
- Recruiting
Kumamoto University Hospital
Kumamoto, 860-8556
- Recruiting
Takano Hospital
Kumamoto, 862-0971
- Recruiting
Kitasato University Kitasato Institute Hospital
Minatoku, 108-8642
- Recruiting
Kyorin University Hospital
Mitaka, 181-8611
- Recruiting
Aichi Medical University Hospital
Nagakute, 480-1195
- Recruiting
Hyogo Medical University Hospital
Nishinomiya, 663 8501
- Recruiting
Oita Red Cross Hospital
Ōita, 870-0033
- Recruiting
National Hospital Organization Osaka National Hospital
Osaka, 540-0006
- Recruiting
Osaka Metropolitan University Hospital
Osaka, 545-8585
- Recruiting
Saga University Hospital
Saga, 849-8501
- Recruiting
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital
Sapporo, 060-0033
- Recruiting
Sapporo Medical University Hospital
Sapporo, 060-8543
- Recruiting
Sapporo Higashi Tokushukai Hospital
Sapporo, 065-0033
- Recruiting
National Hospital Organization Shizuoka Medical Center
Shimizu, 411-8611
- Recruiting
Center Hospital of the National Center for Global Health and Medicine
Shinjuku-ku, 162 8655
- Recruiting
Tokyo Metropolitan Bokutoh Hospital
Sumida Tokyo, 130 8575
- Recruiting
The Jikei University Hospital
Tokyo, 105-8471
- Recruiting
Yamanashi Prefectural Central Hospital
Yamanashi, 400-8506
- Recruiting
Yokohama City University Medical Center
Yokohama, 232 0024
Germany18 sites, 18 recruiting
- Recruiting
Gastroenterologische Spezialpraxis - Berlin-Karlshorst
Berlin, 10318
- Recruiting
Praxis Fur Gastroenteroligie
Berlin, 10825
- Recruiting
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
Berlin, 12203
- Recruiting
Krankenhaus Waldfriede Mitte
Berlin, 14163
- Recruiting
Medizinisches Versorgungszentrum (MVZ) Dachau
Dachau, 85221
- Recruiting
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, 01307
- Recruiting
Universitaetsklinik Erlangen
Erlangen, 91054
- Recruiting
Studiengesellschaft Mitteldeutschland GmbH
Halle, 06108
- Recruiting
Medizinische Hochschule Hannover
Hanover, 30625
- Recruiting
Universitatsklinikum Jena
Jena, 07747
- Recruiting
Gastroenterologie Opernstrasse
Kassel, 34117
- Recruiting
Universitatsklinikum Schleswig Holstein Kiel
Kiel, 24105
- Recruiting
Eugastro GmbH
Leipzig, 04103
- Recruiting
Universitaetsklinikum Mannheim
Mannheim, 68167
- Recruiting
Klinikum Grosshadern Der Ludwig-Maximilians-Universitat
München, 81377
- Recruiting
Klinik und Poliklinik für Innere Medizin II Klinikum rechts an der Isar der TU Muenchen
München, 81675
- Recruiting
Universitaetsmedizin Rostock
Rostock, 18057
- Recruiting
Universitatsklinikum Ulm
Ulm, 89070
Poland17 sites, 17 recruiting
- Recruiting
Centrum Medyczne Medis ManerMed Sp Z O O
Bydgoszcz, 85 229
- Recruiting
Centrum Medyczne Plejady
Krakow, 30 363
- Recruiting
Centrum Medyczne Promed
Krakow, 31-513
- Recruiting
Medrise Sp. z o.o.
Lublin, 20 582
- Recruiting
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie
Lublin, 20-090
- Recruiting
Medicus Zaniewski i Bilski
Olsztyn, 10-684
- Recruiting
Twoja Przychodnia Opolskie Centrum Medyczne
Opole, 45-819
- Recruiting
Centrum Medyczne Medyk
Rzeszów, 35-326
- Recruiting
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, 71-434
- Recruiting
Sonomed Sp. z o.o.
Szczecin, 71-685
- Recruiting
GASTROMED Sp. z o.o.
Torun, 87 100
- Recruiting
H-T Centrum Medyczne
Tychy, 43 100
- Recruiting
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie
Warsaw, 02 781
- Recruiting
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 04 501
- Recruiting
Centrum Medyczne Oporow
Wroclaw, 52 416
- Recruiting
EMC Instytut Medyczny S A Penta Hospitals Przychodnie
Wroclaw, 54-239
- Recruiting
ETG Zamosc
Zamość, 22 400
France15 sites, 15 recruiting
- Recruiting
CHU Amiens
Amiens, 80000
- Recruiting
Hopital Jean Minjoz
Besançon, 25000
- Recruiting
Hopital Beaujon
Clichy, 92110
- Recruiting
APHP - Hopital Henri Mondor
Créteil, 94000
- Recruiting
Hopital de Bicetre
Le Kremlin-Bicêtre, 94270
- Recruiting
CHU de Lille Hopital Claude Huriez
Lille, 59037
- Recruiting
CHU de Montpellier Hopital Saint Eloi
Montpellier, 34090
- Recruiting
CHU de Nantes hotel Dieu
Nantes, 44000
- Recruiting
CHU de Nice Hopital de l Archet 2
Nice, 06202
- Recruiting
Centre Hospitalier Lyon Sud
Oullins, 69495
- Recruiting
Hopital Haut Leveque CHU de Bordeaux
Pessac, 33600
- Recruiting
CHU de Reims
Reims, 51100
- Recruiting
CHU Saint Etienne Hopital Nord
Saint-Priest-en-Jarez, 42270
- Recruiting
CHU Toulouse
Toulouse, 31059
- Recruiting
CHRU de Nancy - Hopitaux de Brabois
Vanduvre-lès-Nancy, 54500
Brazil13 sites, 13 recruiting
- Recruiting
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
Botucatu, 18618-686
- Recruiting
CDC - Centro Digestivo de Curitiba
Curitiba, 80430 180
- Recruiting
CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda
Jaú, 17206-607
- Recruiting
Liga Norte Riograndense Contra O Cancer
Natal, 59062 000
- Recruiting
Complexo Hospitalar de Niteroi
Niterói, 24020-096
- Recruiting
Hospital De Clinicas De Porto Alegre
Porto Alegre, 90035-903
- Recruiting
Hospital Ernesto Dornelles
Porto Alegre, 90160-092
- Recruiting
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
Ribeirão Preto, 14051140
- Recruiting
Pesquisare Saude
Santo André, 09080-110
- Recruiting
BR Trials
São Paulo, 01236 030
- Recruiting
Solare Trials
São Paulo, 01307 002
- Recruiting
Rocco And Nazato Servicos Medicos Ltda
São Paulo, 04077-020
- Recruiting
INTEGRAL Pesquisa e Ensino
Votuporanga, 15500-269
United Kingdom12 sites, 12 recruiting
- Recruiting
Addenbrookes Hospital
Cambridge, CB2 0QQ
- Recruiting
Cardiff and Vale UHB - University Hospital of Wales
Cardiff, CF14 4XW
- Recruiting
Russells Hall Hospital
Dudley, DY1 2HQ
- Recruiting
Ninewells Hospital
Dundee, DD2 1GZ
- Recruiting
Royal Devon & Exeter Hospital
Exeter, EX2 5DW
- Recruiting
Fairfield General Hospital
Great Chart, BL9 7TD
- Recruiting
Whipps Cross University Hospital
Leyton, E11 1NR
- Recruiting
Guys' and St Thomas' NHS Trust
London, SE1 9RT
- Recruiting
Kings College Hospital
London, SE5 9RS
- Recruiting
St Georges Healthcare NHS Trust
London, SW17 0QT
- Recruiting
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP
- Recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 9DU
Canada10 sites, 10 recruiting
- Recruiting
Barrie GI Associates
Barrie, Ontario, L4M 7G1
- Recruiting
South Edmonton Gastroenterology Research Clinic
Edmonton, Alberta, Code: T6K
- Recruiting
Gastroenterology and Internal Medicine Research Institute (GIRI)
Edmonton, Alberta, T5R 1W2
- Recruiting
Charlton Digestive Disease Centre
Hamilton, Ontario, L8N1Y2
- Recruiting
Viable Clinical Research
Kentville, Nova Scotia, B4N 0A3
- Recruiting
London Digestive Disease Institute
London, Ontario, N6K 1M6
- Recruiting
CHUM - Centre hospitalier universitaire de Montreal
Montreal, Quebec, H2X 0C1
- Recruiting
Clinique IMD
Montreal, Quebec, H3H1E3
- Recruiting
Toronto Immune and Digestive Health Institute Inc
Toronto, Ontario, M6A 3B4
- Recruiting
GI Research Institute (G.I.R.I.)
Vancouver, British Columbia, V6Z 2K5
Israel10 sites, 10 recruiting
- Recruiting
Assuta Medical center
Ashdod, 7747629
- Recruiting
Rambam Medical Center
Haifa, 3109601
- Recruiting
Bnai Zion Medical Center
Haifa, 60910
- Recruiting
Wolfson Medical Center
Holon/Tel Aviv, 5822012
- Recruiting
Meir Medical Center
Kefar Sava, 4428164
- Recruiting
Galilee Medical Center
Nahariya, 2210001
- Recruiting
Rabin Medical Center
Petah Tikva, 4941492
- Recruiting
Sheba Medical Center
Ramat Gan, 52621
- Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
- Recruiting
Shaare Zedek Medical Center
Yeruham, 9103102
Australia9 sites, 9 recruiting
- Recruiting
Banksia Trials SA
Adelaide, 5000
- Recruiting
Royal Prince Alfred Hospital
Camperdown, 2050
- Recruiting
Monash Medical Centre
Clayton, 3168
- Recruiting
SA Gastrointestinal Services
Kurraba Point, 5037
- Recruiting
Macquarie University
Macquarie Island, 2109
- Recruiting
Fiona Stanley Hospital
Murdoch, 6150
- Recruiting
John Hunter Hospital
New Lambton, 2305
- Recruiting
Mater Misericordiae Hospital
South Brisbane, 4101
- Recruiting
The Melbourne Gut Clinic Epworth Hospital
West Melbourne, 3002
Belgium9 sites, 9 recruiting
- Recruiting
Imelda Bonheiden
Bonheiden, 2820
- Recruiting
AZ Sint-Lucas
Brugge (Bruges), 8310
- Recruiting
UZ Brussel
Brussel (Bruxelles), 1090
- Recruiting
Cliniques Universitaires Saint Luc
Brussel (Bruxelles), 1200
- Recruiting
AZ Maria Middelares
Gent (Ghent), 9000
- Recruiting
Ghent University Hospital
Gent (Ghent), 9000
- Recruiting
ULB Erasme Ziekenhuis
Koekelberg/Brussel (Bruxelles), 1070
- Recruiting
Universitair Ziekenhuis Leuven
Leuven, 3000
- Recruiting
CHC MontLegia
Liège, 4000
Czechia9 sites, 9 recruiting
- Recruiting
SurGal Clinic
Brno, 602 00
- Recruiting
Nemocnice Ceske Budejovice a s
České Budějovice, 37001
- Recruiting
Gastroenterologie, s.r.o., Hradec Kralove
Hradec Králové, 500 02
- Recruiting
Hepato-gastroenterologie HK, s.r.o.
Hradec Králové, 500 12
- Recruiting
Oblastni nemocnice Kladno a.s.
Kladno, 27259
- Recruiting
Fakultni Nemocnice Ostrava
Ostrava, 70852
- Recruiting
IKEM
Prague, 140 00
- Recruiting
Fakultni Thomayerova nemocnice
Prague, 14000
- Recruiting
ISCARE a.s.
Prague, 190 00
Bulgaria8 sites, 8 recruiting
- Recruiting
MHAT Sv. Karidad EAD
Plovdiv, 4004
- Recruiting
Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
Sofia, 1407
- Recruiting
Diagnostic Consultative Center Neoclinic EAD
Sofia, 1408
- Recruiting
St Ivan Rilski University Multiprofile Hospital For Active Treatment
Sofia, 1431
- Recruiting
University Multiprofile Hospital for Active Treatment - Tsaritsa Yoanna - ISUL, EAD
Sofia, 1527
- Recruiting
DCC Convex EOOD
Sofia, 1680
- Recruiting
Acibadem City Clinic - Oncology Center
Sofia, 1784
- Recruiting
Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
Varna, 9010
India8 sites, 8 recruiting
- Recruiting
Sushruta Multispecialty Hospital and Research Centre
Hubli, 580021
- Recruiting
Asian Institute Of Gastroenterology
Hyderabad, 500032
- Recruiting
S. R. Kalla Memorial General Hospital
Jaipur, 302006
- Recruiting
Lisie Hospital
Kochi, 682018
- Recruiting
P D Hinduja National Hospital and Medical Research Center
Mumbai (ex Bombay), 400016
- Recruiting
Yashoda Super Speciality Hospitals
Secunderabad, 500003
- Recruiting
SIDS Hospital & Research Centre
Surat, 395002
- Recruiting
Gujarat Gastro and Vascular Hospital
Surat, 395009
Turkey (Türkiye)8 sites, 8 recruiting
- Recruiting
Izmir Sehir Hastanesi
?zmir, 35540
- Recruiting
Antalya Training And Research Hospital
Antalya, 07100
- Recruiting
Sanko Universitesi Hastanesi
Gaziantep, 27090
- Recruiting
Bezmialem University Medical Faculty
Istanbul, 34093
- Recruiting
Istanbul University Cerrahpasa Medical Faculty
Istanbul, 34098
- Recruiting
Kocaeli University Medical Faculty
Kocaeli, 41001
- Recruiting
Mersin University Medical Faculty
Mersin, 33343
- Recruiting
Izmir Ataturk Egitim ve Arastirma Hastanesi
Turanköy, 35360
Argentina7 sites, 7 recruiting
- Recruiting
Instituto Medico De Alta Complejidad (IMAC)
Buenos Aires, B1643CRO
- Recruiting
GEDYT
Famailla, C1425BGC
- Recruiting
Globalpsy
La Plata, 1896
- Recruiting
HIGEA
Mendoza, M5500DPS
- Recruiting
Instituto de Investigaciones Clinicas Quilmes
Quilmes, B1878GEG
- Recruiting
Hospital Provincial del Centenario
Rosario, S2000KDS
- Recruiting
MR Medicina Reumatologica
San Fernando, B1646
Italy7 sites, 7 recruiting
- Recruiting
Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano
Milan, 20122
- Recruiting
Ospedale San Raffaele di Milano
Milan, 20132
- Recruiting
Ospedale Sacro Cuore Negrar-Verona
Negrar, 37024
- Recruiting
Azienda Ospedaliera San Camillo-Forlanini
Romagnano, 00152
- Recruiting
Fondazione Policlinico Universitario A Gemelli IRCCS
Romagnano, 00168
- Recruiting
Fatebenefratelli Isola Tiberina - Gemelli Isola
Romagnano, 00186
- Recruiting
Istituto Clinico Humanitas
Rozzano, 20089
Slovakia7 sites, 7 recruiting
- Recruiting
FNsP F. D. Roosevelta Banska Bystrica
Banská Bystrica, 975 17
- Recruiting
Cliniq s.r.o.
Bratislava, 811 09
- Recruiting
ENDOMED s.r.o
Košice, 040 13
- Recruiting
KM Management spol. s r.o.
Nitra, 949 01
- Recruiting
GASTRO I. s.r.o.
Prešov, 080 01
- Recruiting
Gastro LM s.r.o.
Prešov, 080 01
- Recruiting
Ustredna Vojenska Nemocnica SNP Ruzomberok- Fakultna Nemocnica
Ružomberok, 03401
South Korea7 sites, 7 recruiting
- Recruiting
Korea University Ansan Hospital
Ansan, 15355
- Recruiting
Inje University Haeundae Paik Hospital
Busan, 48108
- Recruiting
The Catholic University of Korea Daejeon St Mary's Hospital
Daejeon, 34943
- Recruiting
Samsung Medical Center
Ganggu, 06351
- Recruiting
Seoul National University Hospital
Seoul, 03080
- Recruiting
Asan Medical Center
Seoul, 05505
- Recruiting
Kyung Hee University Hospital
Tongdaemun-Gu, 02447
Hungary6 sites, 6 recruiting
- Recruiting
Obudai Egeszsegugyi Centrum Kft
Budapest, 1036
- Recruiting
Semmelweis Egyetem 1
Budapest, 1082
- Recruiting
Semmelweis Egyetem
Budapest, 1082
- Recruiting
Semmelweis Egyetem 2
Budapest, 1083
- Recruiting
Pannónia Magánorvosi Centrum Kft
Budapest, H-1136
- Recruiting
Szegedi Tudomanyegyetem Aok Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, 6725
Norway6 sites, 6 recruiting
- Recruiting
Alesund sjukehus
Ålesund, 6017
- Recruiting
Sykehuset Innlandet HF Gjøvik
Gjøvik, 2819
- Recruiting
Akershus Universitetssykehus
Lørenskog, 1474
- Recruiting
Sykehuset Ostfold
Moss, 1535
- Recruiting
Universitetssykehuset Nord-Norge HF
Tromsø, 9019
- Recruiting
St. Olavs Hospital
Trondheim, 7030
Romania6 sites, 6 recruiting
- Recruiting
Baneasa Tumor Center Hospital
Bucharest, 013685
- Recruiting
Spitalul Clinic Colentina
Bucharest, 020125
- Recruiting
Institutul Clinic Fundeni
Bucharest, 022328
- Recruiting
Gastro Med S R L
Cluj-Napoca, 400380
- Recruiting
Spitalul Clinic Judetean de Urgente Sf. Spiridon Iasi
Iași, 700111
- Recruiting
Oncohelp Medical Center
Timișoara, 300239
Spain6 sites, 6 recruiting
- Recruiting
Hosp. Gral. Univ. Dr. Balmis
Alicante, 03010
- Recruiting
Hosp. Univ. Infanta Leonor
Madrid, 28031
- Recruiting
Hosp. Clinico Univ. de Santiago
Santiago de Compostela, 15706
- Recruiting
Hosp. Virgen Macarena
Seville, 41009
- Recruiting
Hosp. Alvaro Cunqueiro
Vigo, 36312
- Recruiting
Hosp. Univ. Miguel Servet
Zaragoza, 50009
Greece5 sites, 5 recruiting
- Recruiting
General Hospital of Athens Evaggelismos
Athens, 115 21
- Recruiting
General Hospital Of Athens Korgialenio Benakio H R C
Athens, 11526
- Recruiting
Thoracic General Hospital Of Athens I Sotiria
Athens, 11527
- Recruiting
University General Hospital of Heraklion
Heraklion (Iraklion), 715 00
- Recruiting
Geniko Nosokomeio Peiraia Tzaneio
Piraeus, 18536
Malaysia5 sites, 5 recruiting
- Recruiting
Hospital Ampang
Ampang, 68000
- Recruiting
Sultan Idris Shah Hospital
Kajang, 43000
- Recruiting
Hospital Kuala Lumpur
Kuala Lumpur, 50586
- Recruiting
University Malaya Medical Centre
Kuala Lumpur, 59100
- Recruiting
Hospital Sultanah Nur Zahirah
Kuala Terengganu, 20400
Portugal5 sites, 5 recruiting
- Recruiting
Uls Braga - Hosp. Braga
Braga, 4710 243
- Recruiting
Hosp. Da Luz Lisboa
Lisbon, 1500 650
- Recruiting
Uls Santa Maria - Hosp. Santa Maria
Lisbon, 1649 028
- Recruiting
Uls Algarve Hosp Portimao
Portimão, 8500 338
- Recruiting
Uls Arrabida - Hosp. Sao Bernardo
Setúbal, 2910 549
Taiwan5 sites, 5 recruiting
- Recruiting
Taichung Veterans General Hospital
Taichung, 40705
- Recruiting
National Cheng Kung University Hospital
Tainan, 704
- Recruiting
National Taiwan University Hospital
Taipei, 10002
- Recruiting
Taipei Mackay Memorial Hospital
Taipei, 10449
- Recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan, 333
Austria4 sites, 4 recruiting
- Recruiting
Kepler Universitatsklinikum GmbH
Linz, 4021
- Recruiting
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, 5020
- Recruiting
Krankenhaus der Barmherzigen Brüder
Vienna, 1020
- Recruiting
Klinikum Wels Grieskirchen
Wels, 4600
Mexico4 sites, 4 recruiting
- Recruiting
Centro Medico Clinico Quirurgico Especializado en Investigacion
Guadalajara, 45645
- Recruiting
Morales Vargas Centro de Investigación SC
Léon, 37000
- Recruiting
Centro de Alta Especialidad en Reumatologia e Investigacion
San Luis Potosí City, 78213
- Recruiting
Servicios de Oncología Integral S.A. de C.V.
San Pedro Garza García, 66220
Netherlands4 sites, 4 recruiting
- Recruiting
Vrije Universiteit Medisch Centrum
Amsterdam, 1081 HV
- Recruiting
Radboud Umcn
Nijmegen, 6525 GA
- Recruiting
St. Elisabeth Ziekenhuis
Tilburg, 5022 GC
- Recruiting
UMC Utrecht
Utrecht, 3584 CX
Denmark3 sites, 3 recruiting
- Recruiting
Herlev Hospital
Herlev, 2730
- Recruiting
Hvidovre Hospital
Hvidovre, 2650
- Recruiting
Odense University Hospital
Odense, 5000
Switzerland3 sites, 3 recruiting
- Recruiting
Gastroenterologische Praxis und Crohn-Collitis Zentrum Bern
Bern, 3001
- Recruiting
Kantonsspital St Gallen
Saint Ursen, 9007
- Recruiting
University Hospital Zurich
Zurich, 8091
About this study
Official title: 78934804UCO3001: A Phase 3 Randomized, Double-blind, and Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
- Conditions
- Colitis, Ulcerative
- Being tested
- JNJ-78934804, Guselkumab
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JNJ-78934804Drug
Also called JNJ-4804
JNJ-78934804 will be administered subcutaneously.
GuselkumabDrug
Also called TREMFYA
Guselkumab will be administered subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| JNJ-78934804 | Experimental | Participants will receive JNJ-78934804 induction dose at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase. Receives: Drug: JNJ-78934804 |
| Guselkumab | Active comparator | Participants with moderately to severely active UC will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase. Receives: Drug: JNJ-78934804; Drug: Guselkumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants in Clinical Remission at Week 48
Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1.
Measured: At Week 48
Secondary outcomes (13)
Percentage of Participants with Endoscopic Improvement at Week 48
Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
Measured: At Week 48
Percentage of Participants with Corticosteroid-free (90 day) Clinical Remission at Week 48
Corticosteroid-free (90 day) clinical remission is defined as clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.
Measured: At Week 48
Percentage of Participants Achieving a Combination of Histologic Remission and Endoscopic Improvement at Week 48
Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Histologic remission is defined as an absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system.
Measured: At Week 48
Percentage of Participants with Fatigue Response (PROMIS Fatigue Short Form 7a) at Week 48
Fatigue response is defined as a greater than or equal to (>=) 7- point reduction in the patient-reported outcomes measurement information system (PROMIS) fatigue short form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise).
Measured: At Week 48
Percentage of Participants with Sustained Mayo SF Less Than or Equal to (<=) 1 and RB=0
Percentage of participants with a SF subscore of 0 or 1 and RB subscore of 0 at three assessment time points of Week 12, Week 24, and Week 48 will be reported.
Measured: At Weeks 12, 24, and 48
Percentage of Participants in Abdominal Pain Remission at Week 48
Percentage of participants in abdominal pain remission at week 48 will be reported.
Measured: At Week 48
Change From Baseline in Abdominal Pain Score at Week 48
Change from baseline in abdominal pain score based on abdominal pain-numerical rating scale (AP-NRS) will be reported. NRS is 11 point (0 to 10) scoring system used to evaluate abdominal pain. The score of 0 represents "no pain" and the score of 10 represents "pain as bad as you can imagine", with greater scores indicating greater pain severity and intensity.
Measured: Baseline and Week 48
Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48
IBDQ response is defined as improvement from baseline in the total IBDQ score of >= 16 points. The IBDQ is a 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).
Measured: At Week 48
Percentage of Participants with PROMIS-29 Mental Component Summary (MCS) Response at Week 48
PROMIS 29 MCS response is defined as a >= 7-point improvement from baseline in PROMIS 29 MCS response at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.
Measured: At Week 48
Percentage of Participants in Clinical Remission at Week 12
Clinical remission is defined as an SF subscore of 0 or 1, RB subscore of 0, and an endoscopy subscore of 0 or 1.
Measured: At Week 12
Percentage of Participants with Endoscopic Improvement at Week 12
Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
Measured: At Week 12
Percentage of Participants with Mayo SF/RB Response at Week 2
Mayo SF/RB response is defined as a decrease from baseline in the sum of the SF and the RB subscores by >=30 percent (%) and >= 1 point, with either a >= 1 point decrease from baseline in the RB subscore or an RB subscore of 0 or 1.
Measured: At Week 2
Percentage of Participants with Adverse Events (AE) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.
Measured: Up to approximately 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2026
- Study start23 May 2026
- Primary completion11 Aug 2028 (estimated)
- Study completion16 Oct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colitis, UlcerativeStudies of the same condition, open and under way.
- More trials run by Janssen Research & Development, LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 644 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen Research & Development, LLC Clinical Trial, Study director, Janssen Research & Development, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07577856
- Sponsor's protocol ID
- 78934804UCO3001
- Other IDs
- 78934804UCO3001, 2026-525923-26-00
- Acronym
- DUET ENCORE-UC
- Status last verified
- Nov 2026
- First submitted
- 5 May 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 78934804UCO3001: A Phase 3 Randomized, Double-blind, and Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- ClinicalTrials.gov ID
- NCT07577856
- Acronym / sponsor ID
- DUET ENCORE-UC / 78934804UCO3001
- Conditions
- Colitis, Ulcerative
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 644 participants (estimated)
- Lead sponsor
- Janssen Research & Development, LLCIndustry (pharma, biotech, devices)
- Study start
- 23 May 2026 (actual)
- Primary completion
- 11 Aug 2028 (estimated)
- Study completion
- 16 Oct 2030 (estimated)
- First posted
- 11 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| JNJ-78934804 | Experimental | Drug: JNJ-78934804Participants will receive JNJ-78934804 induction dose at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase. |
| Guselkumab | Active comparator | Drug: JNJ-78934804, Drug: GuselkumabParticipants with moderately to severely active UC will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC.
- Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy
- An endoscopy subscore >=2 as obtained during central review of the screening video endoscopy
- Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies
Key exclusion criteria (5 listed)
- Isolated proctitis (UC limited to the rectum only or to less than [<] 20 centimeter [cm] from the anal verge) as determined during central review of the screening video endoscopy OR Has a diagnosis of isolated proctitis
- Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or any findings suggestive of CD
- Has a history of or ongoing chronic or recurrent infectious disease
- Has previously demonstrated inadequate initial response, loss of response, allergy, hypersensitivity or intolerance to guselkumab or to golimumab
- Is a participant who is pregnant, breastfeeding, or planning to become pregnant, or plans to father a child, while enrolled in this study or within 6 months after the last dose of study intervention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JNJ-78934804Also: JNJ-4804JNJ-78934804 will be administered subcutaneously. | Drug | Guselkumab, JNJ-78934804 |
| GuselkumabAlso: TREMFYAGuselkumab will be administered subcutaneously. | Drug | Guselkumab |
Primary outcome
Percentage of Participants in Clinical Remission at Week 48
Time frame: At Week 48
Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1.
13 secondary outcomes
Percentage of Participants with Endoscopic Improvement at Week 48
Time frame: At Week 48
Percentage of Participants with Corticosteroid-free (90 day) Clinical Remission at Week 48
Time frame: At Week 48
Percentage of Participants Achieving a Combination of Histologic Remission and Endoscopic Improvement at Week 48
Time frame: At Week 48
Percentage of Participants with Fatigue Response (PROMIS Fatigue Short Form 7a) at Week 48
Time frame: At Week 48
Percentage of Participants with Sustained Mayo SF Less Than or Equal to (<=) 1 and RB=0
Time frame: At Weeks 12, 24, and 48
Percentage of Participants in Abdominal Pain Remission at Week 48
Time frame: At Week 48
Change From Baseline in Abdominal Pain Score at Week 48
Time frame: Baseline and Week 48
Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48
Time frame: At Week 48
Percentage of Participants with PROMIS-29 Mental Component Summary (MCS) Response at Week 48
Time frame: At Week 48
Percentage of Participants in Clinical Remission at Week 12
Time frame: At Week 12
Percentage of Participants with Endoscopic Improvement at Week 12
Time frame: At Week 12
Percentage of Participants with Mayo SF/RB Response at Week 2
Time frame: At Week 2
Percentage of Participants with Adverse Events (AE) and Serious AEs (SAEs)
Time frame: Up to approximately 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: Yes. The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Related trials for Colitis, Ulcerative
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Janssen Research & Development, LLC Clinical Trial study director
Janssen Research & Development, LLC
318 sites in 33 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing JNJ-78934804 and Guselkumab in people with Colitis, Ulcerative, run by Janssen Research & Development, LLC at 318 sites in 33 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 318 sites in United States, China, Japan, Germany, Poland and 28 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Contact (844-434-4210, Participate-In-This-Study1@its.jnj.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants in Clinical Remission at Week 48 (time frame: At Week 48). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.